Fig. 1: Lymphocyte kinetics during the first 2 weeks after CAR-T therapy and prognosis. | Leukemia

Fig. 1: Lymphocyte kinetics during the first 2 weeks after CAR-T therapy and prognosis.

From: Implications of lymphocyte kinetics after chimeric antigen receptor T cell therapy for multiple myeloma

Fig. 1

In (A), the median absolute lymphocyte count across the full cohort of patients (N = 133) is presented showing an exponential increase in the population. (B) ALC kinetics in patients treated with Ide-Cel while (C) shows ALC kinetics after Cilta-cel therapy. The kinetics are well described by an exponential function. (D) The area under curve of the ALC count in the first 28 days after CAR-T in patients who did not develop cytokine release syndrome and did not receive any glucocorticosteroids. The AUC is higher for Cilta-cel (p = 0.000892). E Progression free survival was superior in patients with an ALC > 1 × 109/L after CAR-T therapy (p = 0.0061).

Back to article page